Boosting Antitumour Immunity through Targeted Delivery of Interferon-α.
Trends Mol Med
; 25(11): 935-937, 2019 11.
Article
em En
| MEDLINE
| ID: mdl-31624020
ABSTRACT
Immune checkpoint inhibitors (ICIs) have revolutionised cancer immunotherapy but their success is wholly dependent on amplifying an existing immune response directed against the tumour. A recent study by Tsuchiya et al. suggests how the properties of induced pluripotent stem cells (iPSCs) may be exploited for the targeted delivery of interferon-α (IFNα) to elicit an appropriate response.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Interferon-alfa
/
Terapia de Alvo Molecular
/
Imunoterapia
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Trends Mol Med
Ano de publicação:
2019
Tipo de documento:
Article